|
| | ANP 1-28, HUMAN Basic information |
| Product Name: | ANP 1-28, HUMAN | | Synonyms: | ATRIAL NATRIURETIC PEPTIDE HUMAN;SER-LEU-ARG-ARG-SER-SER-CYS-PHE-GLY-GLY-ARG-MET: O-ASP-ARG-ILE-GLY-ALA-GLN-SER-GLY-LEU-GLY-CYS-ASN-SER-PHE-ARG-TYR[SLRRSSCFGGR-MET: O-DRIGAQSGLGCNSFRY]DISULFIDE BRIDGE CYS7-CYS23.;Carperitide Acetate, carperitida;Atrial Natriuretic Peptide (1-28) (human) (trifluoroacetate salt);ahANF, Carperitide;H-Ser-Leu-Arg-Arg-Ser-Ser-Cys-Phe-Gly-Gly-Arg-Met-Asp-Arg-Ile-Gly-Ala-Gln-Ser-Gly-Leu-Gly-Cys-Asn-Ser-Phe-Arg-Tyr-OH;Atrial natriureticpeptide-28 (huMan) (9CI);Atrial Natriuretic Factor (1-28) (huMan)
αhANF, Carperitide | | CAS: | 89213-87-6 | | MF: | C127H203N45O39S3 | | MW: | 3080.44 | | EINECS: | 686-482-9 | | Product Categories: | peptide | | Mol File: | 89213-87-6.mol |  |
| | ANP 1-28, HUMAN Chemical Properties |
| density | 1.55±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Water: 1 mg/ml | | form | A lyophilized powder |
| | ANP 1-28, HUMAN Usage And Synthesis |
| Description | Carperitide is the α-human atrial natriuretic peptide (α-hANP) produced by
recombinant technology. It was introduced in Japan as a treatment for acute
congestive heart failure (CHF). In dogs with CHF, carperitide significantly reduced the
elevated left ventricular end-diastolic pressure and the index of myocardial oxygen
consumption (systolic blood pressure x heart rate). In a clinical trial, carperitide was
effective in improving hemodynamics and symptoms in 60% of patients with acute CHF.
Carperitide was reported to be well tolerated with no significant adverse effects
clinically. A beneficial effect on hemodynamics has been reported in chronic heart
failure patients. Carperitide is also in clinical trials for maintenance of blood pressure
during surgical operations. | | Description | Atrial natriuretic peptide (ANP) is an endogenous peptide generated by proteolysis of prepro-ANP that is secreted by cardiomyocytes in the heart. It has effects on the renal and cardiovascular systems that decrease vasoconstriction, inhibit renin secretion, and increase sodium excretion. Human ANP binds to ANP receptors on cultured vascular smooth muscle cells (VSMCs) with a Kd value of approximately 1-2 nM and increases cGMP levels in a dose-dependent manner. It relaxes potassium-induced contraction of isolated canine renal arterial strips when used at concentrations of 10 and 100 ng/ml and dilates renal arteries in anesthetized dogs when used at doses ranging from 10 to 100 ng/kg. In a rat model of heart failure following experimental autoimmune myocarditis, human ANP, via osmotic mini pump for 28 days, decreases cardiomyocyte size as well as the amount of cardiac fibrosis and left ventricular remodeling. ANP (1-28) (human) is a 28 amino acid peptide corresponding to the human protein sequence. | | Originator | Suntory (Japan) | | Uses | Treatment of decompensated congestive heart
failure. | | Definition | ChEBI: Carperitide is a polypeptide. | | Brand name | Daiichi Suntory, Japan. |
| | ANP 1-28, HUMAN Preparation Products And Raw materials |
|
